Long-term follow-up of people with Parkinson's disease or MSA who received AB-1005
Follows people with Parkinson's disease or MSA who earlier received AB-1005 gene transfer.
Plain-language title generated from the registry record
Registry title: AB-1005 Long-Term Follow-up Study
Key facts
- Where
- Gdansk and Katowice, PolandSee the 2 sites
- Phase
- Phase 4
Where in Poland
- Copernicus Podmiot Leczniczy Sp. z o.oGdansk, PolandNot yet recruiting
- Specjalistyczna Praktyka Lekarska, Prof. Grzegorz OpalaKatowice, PolandNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- AskBio Inc
- Trial code
- NCT07081841EU 2025-522653-19-00
- Record updated
- 2 October 2025
- Original description
This is an observational, long term, follow-up study for participants with Parkinson's disease (PD) or Multiple System Atrophy-Parkinsonian subtype (MSA-P) who participated in prior interventional studies with AB-1005. It is intended to better understand the long-term safety of AB-1005, how well tolerated it is and how long lasting the effects are.Read full original descriptionShow less
Long-Term Safety and Efficacy Follow-up of AB-1005 Gene Transfer Study Participants With Parkinson's Disease or Multiple System Atrophy
This is an observational, long term, follow-up study for participants with Parkinson's disease (PD) or Multiple System Atrophy-Parkinsonian subtype (MSA-P) who participated in prior interventional studies with AB-1005. It is intended to better understand the long-term safety of AB-1005, how well tolerated it is and how long lasting the effects are.
Inclusion: PD and MSA-P participants that are or were enrolled in an interventional AB-1005 study and provide informed consent.
Exclusion: There are no exclusion criteria.